CareDx achieved significant revenue growth, reporting $132 million for Q2 2026, a 52% increase year-over-year. This rise indicates strong demand for its diagnostic services, prompting management to elevate the company's 2026 revenue guidance, further enhancing investor confidence.
Key Highlights
- CareDx's revenue increased by 52% year-over-year to $132 million.
- GAAP net income reached $111 million compared to a net loss of $9 million in Q2 2025.
- The company anticipates full-year 2026 revenue between $490 million and $500 million.
- Testing Services revenue rose 61% year-over-year, reflecting strong market demand.
CareDx, Inc. (NASDAQ: CDNA) reported an impressive revenue increase of $132 million for the second quarter of 2026, marking a 52% boost compared to the same period last year. This growth aligns with analysts' expectations, as CareDx exceeded consensus estimates of $0.24 per share, achieving an earnings per share (EPS) of $0.37. The data showcases the company’s strength in precision diagnostics, driven largely by its expanded offerings in transplant and specialty oncology markets.
The performance underscores a strong market demand for CareDx's products and services, enhancing its positioning within the healthcare sector.
Revenue Breakdown
The second quarter highlighted CareDx's diversified revenue streams, with Testing Services contributing $100 million, up 61% from the previous year. The company processed approximately 58,000 tests, reflecting a 17% increase in testing volume year-over-year. Patient and digital solutions brought in $19 million, signifying a 50% rise, while lab product sales reached $13 million.
The average revenue per test stood at around $1,720. The net income climbed sharply to $111 million, following a significant gain from the sale of its Lab Products business. This strong performance boosts CareDx's overall financial health and validates its product relevance in the evolving healthcare environment.
Market Reaction
Investors have responded favorably to CareDx's solid quarterly results. Year-to-date, the stock has surged significantly, bolstered by a notable increase over the past month. The market capitalization now sits at approximately $2.0 billion.
Comparatively, sector peers have experienced mixed sentiment within the industry. The continued investor confidence in CareDx's growth trajectory signals optimism about future performance, particularly given its improved earnings outlook.
Future Guidance
With the latest quarterly results, CareDx has raised its revenue guidance for the full year of 2026 to a range of $490 million to $500 million, up from the previous forecast. Adjusted EBITDA is also projected to rise between $66 million and $78 million. This upward revision reflects the sustained demand for its testing services and digital solutions.
Looking ahead, investors should closely monitor the upcoming clinical advancement milestones, including the release of updates regarding the AlloHeme® pipeline program. These developments will likely drive additional market interest and impact shareholder value as they unfold later this year.
Peers Moving on This News
- Iovance Biotherapeutics Inc (IOVA) down 1.9%
- Biohaven Ltd (BHVN) up 2.8%
- Zenas Biopharma Inc (ZBIO) down 1.4%
Analysis based on the Form 8-K filed 30 July 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...